Reviva Pharmaceuticals Holdings, Inc. develops therapies for central nervous system, inflammatory and cardiometabolic diseases as a late-stage biopharmaceutical company. News about RVPH centers on brilaroxazine (RP5063), a clinical-stage program for schizophrenia and other neuropsychiatric indications, as well as RP1208, with both drug candidates described as new chemical entities discovered in-house.
Recurring updates include clinical and regulatory communications, intellectual-property strategy, peer-reviewed data publications, corporate presentations, annual and interim financial results, and equity or warrant financings used to support research and development and working capital.
Reviva Pharmaceuticals Holdings (RVPH) reported a narrower third-quarter 2026 net loss while outlining the next development steps for brilaroxazine in schizophrenia. Net loss was $2,298,905, or $0.17 per share, versus $4,010,773, or $1.09 per share, a year earlier. Cash and cash equivalents rose to $17,458,418 at September 30 from $14,438,792 at December 31, 2025.
Reviva expects FDA feedback in Q4 2026 on its proposed new formulation for RECOVER-2 and a future drug approval application. It plans a study to confirm formulation comparability in Q1 2027 following that feedback, and targets Phase 3 enrollment in 1H 2027, subject to additional financing. The new formulation's patent application received priority examination, with potential protection through 2046. Share figures reflect a 1-for-20 reverse split effective March 9, 2026.
Reviva Pharmaceuticals (RVPH) will participate in the virtual Lytham Partners Fall 2026 Investor Conference with a webcast presentation on September 29, 2026, at 12:30 PM ET.
The presentation can be accessed via the conference website or a direct webinar link and will be available for replay. Management will also hold virtual one-on-one meetings with investors during the September 29–30, 2026 event.
Reviva (OTCQB: RVPH) reported Q2 2026 net loss of approximately $2.4 million, or $0.19 per share, a reduction from about $6.1 million, or $2.40 per share, in Q2 2025. Operating expenses fell to roughly $2.6 million from $6.1 million, reflecting lower R&D and G&A spending.
As of June 30, 2026, cash and cash equivalents totaled about $19.9 million, up from $14.4 million at year-end 2025, with total stockholders’ equity rising to $15.2 million. Shares outstanding increased to 13.1 million from 5.9 million, after a 1-for-20 reverse stock split in March 2026.
Reviva filed a U.S. composition of matter patent application for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046. FDA feedback on use of this formulation in the RECOVER‑2 Phase 3 trial and planned NDA is expected in Q4 2026, with a bioequivalence study also targeted for Q4 2026. Patient enrollment in RECOVER‑2 for schizophrenia is planned for 1H 2027, subject to additional financing.
Reviva (OTCQB: RVPH) announced that Founder, President and CEO Laxminarayan Bhat, PhD, will join a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase on Wednesday, May 20, 2026, from 2:40–3:00 PM ET. Investors can register to watch the session online.
Reviva (RVPH) reported first quarter 2026 results and development progress for brilaroxazine. Net loss was about $3.2 million ($0.46/share), versus $6.4 million ($2.61/share) a year earlier. Cash and equivalents rose to $22.2 million from $14.4 million.
The company filed a U.S. composition of matter provisional patent for a new form of brilaroxazine potentially extending exclusivity to 2046, and expects FDA feedback on its use in the RECOVER-2 Phase 3 schizophrenia trial and future NDA in mid‑2026. Patient enrollment in RECOVER-2 is expected to start in Q3 2026.
Reviva completed a $10.0 million public equity offering in March 2026 and plans partnership discussions. Its common stock is set to transition from a Nasdaq listing to OTCQB on May 14, 2026, with ticker RVPH unchanged.
Reviva (NASDAQ: RVPH) announced that CEO Laxminarayan Bhat, PhD, will participate in an A.G.P. fireside chat on April 27, 2026 at 11:00 AM ET to discuss the clinical-stage drug candidate brilaroxazine and upcoming clinical, regulatory, and IP milestones.
A live webcast link is available for investors and interested parties to watch the discussion.
Reviva Pharmaceuticals (NASDAQ: RVPH) published a shareholder letter on April 15, 2026 outlining recent financing, clinical and IP actions to advance brilaroxazine. The company closed a $10 million financing and reported ~$23 million in cash, targeting funding into Q1 2027.
Key priorities: pursue FDA alignment on a new API/form to extend exclusivity (potentially through 2046), file a composition-of-matter patent, initiate RECOVER-2 Phase 3 activities in Q2 2026, and begin U.S. enrollment in Q3 2026 with expected study completion in Q4 2027.
Reviva (NASDAQ: RVPH) reported full-year 2025 results and business updates on March 30, 2026. The company disclosed a net loss of $19.9M for 2025 and cash of $14.4M at year-end. Reviva received FDA written recommendations calling for a second Phase 3 trial and plans to initiate RECOVER-2 in mid-2026. The company completed NDA-enabling studies, cGMP registration manufacturing, and raised gross proceeds from public offerings in 2025–2026.
Reviva Pharmaceuticals (NASDAQ: RVPH) closed a public offering on March 20, 2026, raising approximately $10.0 million gross by selling 6,666,667 common shares with accompanying Series G and Series H warrants at a combined price of $1.50 per share and warrant package.
The Series G and H warrants have a $1.50 exercise price; G warrants expire in five years and H warrants expire in 12 months. The company reported approximately $23 million cash post-close, which it believes funds operations into Q1 2027, and intends to use proceeds to fund R&D including the RECOVER-2 Phase 3 trial for brilaroxazine, plus working capital.
Reviva Pharmaceuticals (NASDAQ: RVPH) priced a public offering to raise approximately $10.0 million by selling 6,666,667 common shares with attached Series G and Series H warrants at a combined price of $1.50 per share and warrant.
The Series G and Series H warrants have an exercise price of $1.50; G warrants expire five years and H warrants expire 12 months from issuance. Closing is expected on or about March 20, 2026. The company intends to use proceeds to fund R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and general corporate purposes.